top of page

Agreement expands the company strategy to employ the immune system in the development of cancer therapies


RIEHEN, SWITZERLAND, April 7, 2022 ─ Ymmunobio AG, a preclinical stage biotech company specializing in the development of CEACAM antibodies as anti-cancer treatments, today announced that it has signed a purchase agreement with LeukoCom GmbH, Essen, Germany. Under the terms of the agreement, Ymmunobio acquires the patents and intellectual property to several CEACAM antibodies, including YB-200, which is currently in preclinical development as an immune-agonistic CEACAM1 antibody for the potential treatment of melanoma and other solid tumors.


"We are excited to obtain the patent rights to the new immune-agonistic CEACAM antibodies,” said Dr. Katrin Rupalla, CEO, Ymmunobio AG. “There are potential significant advantages for the treatment of solid tumors in leveraging both the physiological and pathophysiological roles of CEACAMs. This broader mechanism is a benefit as compared to other CEACAM antibodies and novel checkpoint inhibitors currently in development.”


Ymmunobio AG has the rights to CEACAM1 antibodies YB-200, YB-300, YB-400 and one additional antibody targeting CEACAM8. It will also have the rights to all future CEACAM-related patents developed or secured by LeukoCom GmbH.


ABOUT YMMUNOBIO

Ymmunobio AG, a preclinical stage oncology biotech company, was founded by Dr. Katrin Rupalla and is committed to developing a proprietary class of CEACAM antibodies to increase the efficiency of the adaptive and innate immune system to fight cancer. Ymmunobio’s research targets defined CEACAM receptor isoforms that play a major role in the immune response and cancer cell evolution. The company’s proprietary platform is based on the leading research of Dr. Bernhard B. Singer, University Essen/Duisburg, Germany.


Contact: Dr. Katrin Rupalla, info@ymmuno.bio

Dr. Skubitz, Professor for Hematology & Oncology, University of Minnesota, joins Ymmunobio as scientific advisor for development of CEACAM antibodies,


RIEHEN, SWITZERLAND, January 17, 2022 ─ Ymmunobio AG, a preclinical stage biotech company specializing in the development of CEACAM antibodies as anti-cancer treatments, today announced the appointment of Dr. Keith Skubitz as a scientific advisor. Dr. Skubitz’s appointment reinforces the company’s strategy to employ the immune system to develop cancer therapies.


Keith Skubitz, MD, professor of Hematology, Oncology, and Transplantation at the University of Minnesota, has directed multiple clinical trials and has extensive experience in the clinical management of sarcomas. His research interests are focused on three main areas: the biology and treatment of sarcomas; drug development; and immunology, including the biology of the CEACAM family.


“I’m excited to join Ymmunobio as a scientific advisor,” said Dr. Skubitz. “I look forward to leveraging Ymmunobio’s proprietary platform to deploy the unique functioning of CEACAM antibodies in the immune system and develop them as a novel treatment for cancer.”


Dr. Skubitz was heavily involved in the Leukocyte Differentiation Antigen Workshops related to CEACAMs. He coordinated the CD15, CD66, and CD67 groups, where he made several important observations. Dr. Skubitz has published 157 manuscripts and 33 book chapters.


ABOUT YMMUNOBIO

Ymmunobio AG, a preclinical stage oncology biotech company developing a proprietary class of CEACAM1 antibodies to increase the efficiency of the adaptive and innate immune system to fight cancer. Ymmunobio’s research targets the CEACAM receptors that play a major role in the immune response and cancer cell evolution. The company’s proprietary platform is based on the leading research of Dr. Bernhard B. Singer, University Essen/Duisburg, Germany.

NEWS

Our science is making news.
Stay in touch.

Follow us on LinkedIn.

Join our mailing list

Thanks for subscribing!

bottom of page